title: Performance of the digene LQ, RH and PS HPVs genotyping systems on clinical samples and comparison with HC2 and PCR-based Linear Array.
abstract: BACKGROUND
  Certain Human Papillomaviruses (HPVs) are the infectious agents involved in cervical cancer development. Detection of HPVs DNA is part of the cervical cancer screening protocols and HPVs genotyping has been proposed for its inclusion in these preventive programs. The aim of this study was to evaluate three novel genotyping tests, namely Qiagen LQ, RH and PS, in clinical samples with and without abnormalities. For this, 305 cervical samples were processed and the results of the evaluated techniques were compared with those obtained in the HPVs diagnostic process in our lab, by using HC2 and Linear Array (LA) technologies.
  
  
  RESULTS
  The concordances and kappa statistics (k) for each technique compared with HC2 were 98.69% (k = 0.94) for LQ, 98.03% (k = 0.91) for RH and 91.80% (k = 0.82) for PS. There was a very good agreement in HPVs type-specific concordance for the most prevalent types HPV16 (kappa range = 0.83-0.90), HPV18 (k.r.= 0.74-0.80) and HPV45 (k.r.= 0.82-0.90).
  
  
  CONCLUSIONS
  The three tests showed an overall good concordance for HPVs detection when compared with HR-HC2 system. LQ and RH rendered lower detection rate for multiple infections than LA genotyping. However, our understanding of the clinical significance of multiple HPVs infections is still incomplete and therefore the relevance of the lower ability to detect multiple infections needs to be evaluated.
authors.affiliation: Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Program (CERP), IDIBELL, Catalan Institute of Oncology (ICO), (Gran Via 199-203), l'Hospitalet de Llobregat (08907, Barcelona), Spain. jmgodinez@iconcologia.net.
authors.forename: Jose M
authors.initials: JM
authors.lastname: Godínez
authors.forename: Sara
authors.initials: S
authors.lastname: Tous
authors.forename: Nuria
authors.initials: N
authors.lastname: Baixeras
authors.forename: Judith
authors.initials: J
authors.lastname: Moreno-Crespi
authors.forename: María
authors.initials: M
authors.lastname: Alejo
authors.forename: Marylène
authors.initials: M
authors.lastname: Lejeune
authors.forename: Ignacio G
authors.initials: IG
authors.lastname: Bravo
authors.forename: F Xavier
authors.initials: FX
authors.lastname: Bosch
authors.forename: Silvia
authors.initials: S
authors.lastname: de Sanjosé
references.citation: J Virol Methods. 2007 Jul;143(1):45-54
references.pmid: 17399803
references.citation: J Clin Pathol. 2009 Oct;62(10):870-8
references.pmid: 19706632
references.citation: N Engl J Med. 2009 Apr 2;360(14):1385-94
references.pmid: 19339719
references.citation: J Clin Microbiol. 2008 Oct;46(10):3437-45
references.pmid: 18716224
references.citation: Int J Cancer. 2009 Apr 1;124(7):1626-36
references.pmid: 19115209
references.citation: Am J Clin Pathol. 2004 Jul;122(1):90-3
references.pmid: 15272535
references.citation: Virology. 2010 May 25;401(1):70-9
references.pmid: 20206957
references.citation: Diagn Mol Pathol. 2010 Dec;19(4):218-23
references.pmid: 21051999
references.citation: Expert Rev Anti Infect Ther. 2010 Oct;8(10):1139-62
references.pmid: 20954880
references.citation: Vaccine. 2006 Aug 31;24 Suppl 3:S3/35-41
references.pmid: 16950016
references.citation: J Clin Microbiol. 2006 Jun;44(6):1998-2006
references.pmid: 16757590
references.citation: J Clin Virol. 2011 Apr;50(4):276-80
references.pmid: 21296612
references.citation: BMJ. 1999 Apr 3;318(7188):904-8
references.pmid: 10102852
references.citation: Am J Clin Pathol. 2005 Nov;124(5):722-32
references.pmid: 16203281
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1248-54
references.pmid: 18483347
references.citation: J Clin Microbiol. 2006 Sep;44(9):3292-8
references.pmid: 16954263
references.citation: Br J Cancer. 2004 Aug 31;91(5):942-53
references.pmid: 15292939
references.citation: J Clin Virol. 2009 Nov;46 Suppl 3:S21-6
references.pmid: 20129070
references.citation: J Clin Microbiol. 1997 Jun;35(6):1304-10
references.pmid: 9163434
references.citation: Lancet Oncol. 2010 Nov;11(11):1048-56
references.pmid: 20952254
references.citation: J Clin Microbiol. 2006 Nov;44(11):3915-7
references.pmid: 16971652
references.citation: J Pathol. 2003 Sep;201(1):1-6
references.pmid: 12950011
references.citation: N Engl J Med. 2003 Feb 6;348(6):518-27
references.pmid: 12571259
references.citation: J Clin Virol. 2009 Oct;46(2):176-9
references.pmid: 19683958
references.citation: Int J Cancer. 2009 Feb 1;124(3):516-20
references.pmid: 18973271
references.citation: Clin Infect Dis. 2008 Sep 1;47(5):610-5
references.pmid: 18637758
references.citation: Gynecol Oncol. 2006 Oct;103(1):12-7
references.pmid: 16934860
references.citation: J Clin Virol. 2009 Nov;46 Suppl 3:S16-20
references.pmid: 20129069
references.citation: BMJ. 2008 Oct 13;337:a1754
references.pmid: 18852164
references.citation: Arch Pathol Lab Med. 2010 Dec;134(12):1813-7
references.pmid: 21128780
references.citation: Am J Clin Pathol. 2004 Aug;122(2):238-45
references.pmid: 15323141
references.citation: J Pathol. 1999 Sep;189(1):12-9
references.pmid: 10451482
references.citation: Lancet Oncol. 2009 Jul;10(7):672-82
references.pmid: 19540162
references.citation: Biometrics. 1977 Mar;33(1):159-74
references.pmid: 843571